Advertisement

Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers

Published:November 04, 2022DOI:https://doi.org/10.1016/j.hpb.2022.11.003

      Abstract

      Background

      We described trends and disparities in utilization of systemic chemotherapy in metastatic hepato-pancreato-biliary (HPB) cancers.

      Methods

      We queried the National Cancer Database for metastatic HPB cancers [hepatocellular carcinoma (HCC), biliary tract cancers (BTC), pancreatic adenocarcinoma (PDAC)]. We used multivariable analysis to examine the factors associated with utilization of systemic chemotherapy. We utilized marginal structural logistic models to estimate the effect of health insurance, facility type, or facility volume on utilization of systemic chemotherapy.

      Results

      We identified 162,283 patients with metastatic HPB cancers: 23,923 (14.7%) had HCC, 26,766 (16.5%) had BTC, and 111,594 (68.8%) had PDAC.
      A total of 37.2% patients with HCC, 55.6% with BTC, and 56.4% with PDAC received chemotherapy. Age ≥70 years and Charlson-Deyo score ≥2 were associated with lower likelihood of receiving chemotherapy across all cancers.
      Patients with private health insurance had higher receipt of chemotherapy. Receiving treatment at academic facilities had no effect on the receipt of chemotherapy. Treatment of patients with HCC or PDAC at high-volume facilities resulted in higher receipt of chemotherapy.

      Conclusion

      A significant proportion of patients with metastatic HPB cancers do not receive systemic chemotherapy. Several disparities in administration of chemotherapy for metastatic HPB cancers exist.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Freelove R.
        • Walling A.D.
        Pancreatic cancer: diagnosis and management.
        Am Fam Physician. 2006; 73: 485-492
        • Patel T.
        Cholangiocarcinoma--controversies and challenges.
        Nat Rev Gastroenterol Hepatol. 2011; 8: 189-200https://doi.org/10.1038/nrgastro.2011.20
        • Recio-Boiles A.
        • Babiker H.M.
        Liver cancer. StatPearls.
        in: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)2022
        • Ghaneh P.
        • Costello E.
        • Neoptolemos J.P.
        Biology and management of pancreatic cancer.
        Gut. 2007; 56: 1134-1152https://doi.org/10.1136/gut.2006.103333
        • Pang R.W.
        • Joh J.W.
        • Johnson P.J.
        • Monden M.
        • Pawlik T.M.
        • Poon R.T.
        Biology of hepatocellular carcinoma.
        Ann Surg Oncol. 2008; 15: 962-971https://doi.org/10.1245/s10434-007-9730-z
        • Tariq N.U.
        • McNamara M.G.
        • Valle J.W.
        Biliary tract cancers: current knowledge, clinical candidates and future challenges.
        Cancer Manag Res. 2019; 11: 2623-2642https://doi.org/10.2147/CMAR.S157092
        • She W.H.
        • Chok K.
        Strategies to increase the resectability of hepatocellular carcinoma.
        World J Hepatol. 2015; 7: 2147-2154https://doi.org/10.4254/wjh.v7.i18.2147
        • Cidon E.U.
        Resectable cholangiocarcinoma: reviewing the role of adjuvant strategies.
        Clin Med Insights Oncol. 2016; 10: 43-48https://doi.org/10.4137/CMO.S32821
        • Lopez N.E.
        • Prendergast C.
        • Lowy A.M.
        Borderline resectable pancreatic cancer: definitions and management.
        World J Gastroenterol. 2014; 20: 10740-10751https://doi.org/10.3748/wjg.v20.i31.10740
        • Fairweather M.
        • Balachandran V.P.
        • D'Angelica M.I.
        Surgical management of biliary tract cancers.
        Chin Clin Oncol. 2016; 5: 63https://doi.org/10.21037/cco.2016.10.03
        • Hsu C.Y.
        • Lee Y.H.
        • Hsia C.Y.
        • Huang Y.H.
        • Su C.W.
        • Lin H.C.
        • et al.
        Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system.
        Hepatology. 2013; 57: 112-119https://doi.org/10.1002/hep.25950
        • Molinari M.
        • El-Tawil K.
        • Swaid F.
        • Fiorentini G.
        • Bou-Samra P.
        • Sharma C.
        • et al.
        Patients’ treatment preferences for potentially resectable tumors of the head of the pancreas.
        HPB. 2020; 22: 265-274https://doi.org/10.1016/j.hpb.2019.06.015
        • Siddique O.
        • Yoo E.R.
        • Perumpail R.B.
        • Perumpail B.J.
        • Liu A.
        • Cholankeril G.
        • et al.
        The importance of a multidisciplinary approach to hepatocellular carcinoma.
        J Multidiscip Healthc. 2017; 10: 95-100https://doi.org/10.2147/JMDH.S128629
        • Liu Y.
        • Xue X.
        Systematic review of peri-operative nutritional support for patients undergoing hepatobiliary surgery.
        Hepatobiliary Surg Nutr. 2015; 4: 304-312https://doi.org/10.3978/j.issn.2304-3881.2014.12.09
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • Bouche O.
        • Guimbaud R.
        • Becouarn Y.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825https://doi.org/10.1056/NEJMoa1011923
        • Horgan A.M.
        • Amir E.
        • Walter T.
        • Knox J.J.
        Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.
        J Clin Oncol. 2012; 30: 1934-1940https://doi.org/10.1200/JCO.2011.40.5381
        • Wrzesinski S.H.
        • Taddei T.H.
        • Strazzabosco M.
        Systemic therapy in hepatocellular carcinoma.
        Clin Liver Dis. 2011; 15 (vii-x): 423-441https://doi.org/10.1016/j.cld.2011.03.002
        • Bagante F.
        • Gani F.
        • Beal E.W.
        • Merath K.
        • Chen Q.
        • Dillhoff M.
        • et al.
        Prognosis and adherence with the national comprehensive cancer Network guidelines of patients with biliary tract cancers: an analysis of the national cancer database.
        J Gastrointest Surg. 2019; 23: 518-528https://doi.org/10.1007/s11605-018-3912-9
        • David J.M.
        • Ho A.S.
        • Luu M.
        • Yoshida E.J.
        • Kim S.
        • Mita A.C.
        • et al.
        Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
        Cancer. 2017; 123: 3933-3942https://doi.org/10.1002/cncr.30843
        • Joshi S.S.
        • Handorf E.A.
        • Zibelman M.
        • Plimack E.R.
        • Uzzo R.G.
        • Kutikov A.
        • et al.
        Treatment facility volume and survival in patients with metastatic renal cell carcinoma: a registry-based analysis.
        Eur Urol. 2018; 74: 387-393https://doi.org/10.1016/j.eururo.2018.05.025
        • Joshi S.S.
        • Handorf E.R.
        • Sienko D.
        • Zibelman M.
        • Uzzo R.G.
        • Kutikov A.
        • et al.
        Treatment facility volume and survival in patients with advanced prostate cancer.
        Eur Urol Oncol. 2020; 3: 104-111https://doi.org/10.1016/j.euo.2019.06.016
        • Ellis L.
        • Canchola A.J.
        • Spiegel D.
        • Ladabaum U.
        • Haile R.
        • Gomez S.L.
        Trends in cancer survival by health insurance status in California from 1997 to 2014.
        JAMA Oncol. 2018; 4: 317-323https://doi.org/10.1001/jamaoncol.2017.3846
        • Huang L.F.
        • Hong A.
        • Cioffi G.
        • Alahmadi A.
        • Tang T.Y.
        • Ocuin L.M.
        • et al.
        Associations of racial and ethnic category, age, comorbidities, and socioeconomic factors on concordance to NCCN guidelines for patients with high-risk biliary tract cancers after surgery.
        Front Oncol. 2022; 12771688https://doi.org/10.3389/fonc.2022.771688
        • Sweigert P.J.
        • Eguia E.
        • Baker M.S.
        • Paredes A.Z.
        • Tsilimigras D.I.
        • Dillhoff M.
        • et al.
        Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma.
        J Surg Oncol. 2020; 121: 936-944https://doi.org/10.1002/jso.25861
        • Uhlig J.
        • Sellers C.M.
        • Khan S.A.
        • Cha C.
        • Kim H.S.
        Hepatocellular carcinoma: impact of academic setting and hospital volume on patient survival.
        Surg Oncol. 2019; 31: 111-118https://doi.org/10.1016/j.suronc.2019.10.009
        • Khanal N.
        • Upadhyay S.
        • Dahal S.
        • Bhatt V.R.
        • Silberstein P.T.
        Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base.
        Ther Adv Med Oncol. 2015; 7: 198-205https://doi.org/10.1177/1758834015579313
      1. American College of Surgeons. The national cancer database 2018 PUF data dictionary. https://bit.ly/33Y8HWE. Accessed August 2, 2022.

        • Keung E.Z.
        • Chiang Y.J.
        • Cormier J.N.
        • Torres K.E.
        • Hunt K.K.
        • Feig B.W.
        • et al.
        Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma.
        Cancer. 2018; 124: 4495-4503https://doi.org/10.1002/cncr.31699
        • Naffouje S.A.
        • Ali M.A.
        • Kamarajah S.K.
        • White B.
        • Salti G.I.
        • Dahdaleh F.
        Assessment of textbook oncologic outcomes following proctectomy for rectal cancer.
        J Gastrointest Surg. 2022; 26: 1286-1297https://doi.org/10.1007/s11605-021-05213-9
        • Wang S.
        • Lai S.
        • von Itzstein M.S.
        • Yang L.
        • Yang D.M.
        • Zhan X.
        • et al.
        Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer.
        Cancer. 2019; 125: 4252-4259https://doi.org/10.1002/cncr.32377
        • Lamarca A.
        • Palmer D.H.
        • Wasan H.S.
        • Ross P.J.
        • Ma Y.T.
        • Arora A.
        • et al.
        Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
        Lancet Oncol. 2021; 22: 690-701https://doi.org/10.1016/S1470-2045(21)00027-9
        • Chapman B.C.
        • Paniccia A.
        • Hosokawa P.W.
        • Henderson W.G.
        • Overbey D.M.
        • Messersmith W.
        • et al.
        Impact of facility type and surgical volume on 10-year survival in patients undergoing hepatic resection for hepatocellular carcinoma.
        J Am Coll Surg. 2017; 224: 362-372https://doi.org/10.1016/j.jamcollsurg.2016.11.011
        • Jaap K.
        • Fluck M.
        • Hunsinger M.
        • Wild J.
        • Arora T.
        • Shabahang M.
        • et al.
        Analyzing the impact of compliance with national guidelines for pancreatic cancer care using the national cancer database.
        J Gastrointest Surg. 2018; 22: 1358-1364https://doi.org/10.1007/s11605-018-3742-9
        • Upadhyay S.
        • Dahal S.
        • Bhatt V.R.
        • Khanal N.
        • Silberstein P.T.
        Chemotherapy use in stage III colon cancer: a National Cancer Database analysis.
        Ther Adv Med Oncol. 2015; 7: 244-251https://doi.org/10.1177/1758834015587867
        • Austin P.C.
        • Stuart E.A.
        Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.
        Stat Med. 2015; 34: 3661-3679https://doi.org/10.1002/sim.6607
        • Tennant P.W.G.
        • Murray E.J.
        • Arnold K.F.
        • Berrie L.
        • Fox M.P.
        • Gadd S.C.
        • et al.
        Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations.
        Int J Epidemiol. 2021; 50: 620-632https://doi.org/10.1093/ije/dyaa213
        • Kikuchi L.
        • Chagas A.L.
        • Alencar R.
        • Tani C.
        • Diniz M.A.
        • D’Albuquerque L.A.C.
        • et al.
        Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage.
        Clinics. 2017; 72: 454-460https://doi.org/10.6061/clinics/2017(08)01
      2. National Comperhensive Cancer Network. NCCN guidelines for biliary tract cancers. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed August 2, 2022.

      3. National Comperhensive Cancer Network. NCCN guidelines for pancreatic adenocarcnioma. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed August 2, 2022.

        • Busch E.L.
        • Martin C.
        • DeWalt D.A.
        • Sandler R.S.
        Functional health literacy, chemotherapy decisions, and outcomes among a colorectal cancer cohort.
        Cancer Control. 2015; 22: 95-101https://doi.org/10.1177/107327481502200112
        • Puts M.T.
        • Tapscott B.
        • Fitch M.
        • Howell D.
        • Monette J.
        • Wan-Chow-Wah D.
        • et al.
        A systematic review of factors influencing older adults’ decision to accept or decline cancer treatment.
        Cancer Treat Rev. 2015; 41: 197-215https://doi.org/10.1016/j.ctrv.2014.12.010
        • Llovet J.M.
        • Ricci S.
        • Mazzaferro V.
        • Hilgard P.
        • Gane E.
        • Blanc J.F.
        • et al.
        Sorafenib in advanced hepatocellular carcinoma.
        N Engl J Med. 2008; 359: 378-390https://doi.org/10.1056/NEJMoa0708857
        • Finn R.S.
        • Qin S.
        • Ikeda M.
        • Galle P.R.
        • Ducreux M.
        • Kim T.Y.
        • et al.
        Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
        N Engl J Med. 2020; 382: 1894-1905https://doi.org/10.1056/NEJMoa1915745
        • Ward M.M.
        • Ullrich F.
        • Matthews K.
        • Rushton G.
        • Tracy R.
        • Bajorin D.F.
        • et al.
        Access to chemotherapy services by availability of local and visiting oncologists.
        J Oncol Pract. 2014; 10: 26-31https://doi.org/10.1200/JOP.2013.001217
        • Bilimoria K.Y.
        • Bentrem D.J.
        • Ko C.Y.
        • Stewart A.K.
        • Winchester D.P.
        • Talamonti M.S.
        National failure to operate on early stage pancreatic cancer.
        Ann Surg. 2007; 246: 173-180https://doi.org/10.1097/SLA.0b013e3180691579
        • Watson M.D.
        • Baimas-George M.R.
        • Murphy K.J.
        • Pickens R.C.
        • Iannitti D.A.
        • Martinie J.B.
        • et al.
        Pure and hybrid deep learning models can predict pathologic tumor response to neoadjuvant therapy in pancreatic adenocarcinoma: a pilot study.
        Am Surg. 2021; 87: 1901-1909https://doi.org/10.1177/0003134820982557
        • Warner E.T.
        • Park E.R.
        • Luberto C.M.
        • Rabin J.
        • Perez G.K.
        • Ostroff J.S.
        Internalized stigma among cancer patients enrolled in a smoking cessation trial: the role of cancer type and associations with psychological distress.
        Psycho Oncol. 2022; 31: 753-760https://doi.org/10.1002/pon.5859
        • Lu P.
        • Fields A.C.
        • Meyerhardt J.A.
        • Davids J.S.
        • Shabat G.
        • Bleday R.
        • et al.
        Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma.
        J Surg Oncol. 2019; 120: 446-451https://doi.org/10.1002/jso.25599
        • Craigs C.L.
        • Bennett M.I.
        • Hurlow A.
        • West R.M.
        • Ziegler L.E.
        Older age is associated with less cancer treatment: a longitudinal study of English cancer patients.
        Age Ageing. 2018; 47: 833-840https://doi.org/10.1093/ageing/afy094
        • Parikh-Patel A.
        • Morris C.R.
        • Kizer K.W.
        Disparities in quality of cancer care: the role of health insurance and population demographics.
        Medicine. 2017; 96e9125https://doi.org/10.1097/MD.0000000000009125
        • Krell R.W.
        • Regenbogen S.E.
        • Wong S.L.
        Variation in hospital treatment patterns for metastatic colorectal cancer.
        Cancer. 2015; 121: 1755-1761https://doi.org/10.1002/cncr.29253
        • MacKinney E.C.
        • Holoubek S.A.
        • Khokar A.M.
        • Kuchta K.M.
        • Moo-Young T.A.
        • Prinz R.A.
        • et al.
        Treatment differences at high volume centers and low volume centers in non-metastatic and metastatic adrenocortical carcinoma.
        Am J Surg. 2022; 223: 582-586https://doi.org/10.1016/j.amjsurg.2022.01.004
      4. M. Elshami, F.A. Ahmed, H. Kakish, J.J. Hue, R.S. Hoehn, L.D. Rothermel, et al. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. HPB. doi:10.1016/j.hpb.2022.07.007

        • Idrees J.J.
        • Merath K.
        • Gani F.
        • Bagante F.
        • Mehta R.
        • Beal E.
        • et al.
        Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma.
        HPB. 2019; 21: 981-989https://doi.org/10.1016/j.hpb.2018.11.013
        • O’Mahoney P.R.A.
        • Yeo H.L.
        • Sedrakyan A.
        • Trencheva K.
        • Mao J.
        • Isaacs A.J.
        • et al.
        Centralization of pancreatoduodenectomy a decade later: impact of the volume-outcome relationship.
        Surgery. 2016; 159: 1528-1538https://doi.org/10.1016/j.surg.2016.01.008
        • Sheetz K.H.
        • Dimick J.B.
        • Nathan H.
        Centralization of high-risk cancer surgery within existing hospital systems.
        J Clin Oncol. 2019; 37: 3234-3242https://doi.org/10.1200/JCO.18.02035
        • Maegawa F.B.
        • Ashouri Y.
        • Bartz-Kurycki M.
        • Ahmad M.
        • De La Rosa E.
        • Philipovskiy A.
        • et al.
        Impact of facility type on survival after pancreatoduodenectomy for small pancreatic adenocarcinoma (</= 2 cm).
        Am J Surg. 2021; 222: 145-152https://doi.org/10.1016/j.amjsurg.2020.10.022
        • Hartigan K.
        Patient education: the cornerstone of successful oral chemotherapy treatment.
        Clin J Oncol Nurs. 2003; 7: 21-24https://doi.org/10.1188/03.CJON.S6.21-24